Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Affinitak plus Gemcitabine and Cisplatin in Advanced NSCLC
NCT00034268Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2002
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of aprinocarsen in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Mar 2002; status: completed.
02
Drugs
aprinocarsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00034268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034268.